In several early-phase randomized clinical trials, the application of pembrolizumab and nivolumab (PD-L1/PD-1 blockage) suggested promising clinical outcomes for CESC patients with metastasis and recurrence (Frenel et al., 2017; Chung et al., 2019). This evidence concerns the gene CD274 and cervical squamous cell carcinoma.